Get started

Pharmastocks

SYNCOMF FOR 3-6 MONTHSFor 3-6 Months Fundamentally, > Revenue Growth over 60% Quarterly > Net Income Growth over 70% Quarterly > EPS over 40% Yearly Technically, > Trading at the point of historically tested demand zone. > Rising relative strength. > Market Profile also suggesting an upmove. > Current levels suggests buyer's entry with volumes. Risk to Reward is 1:2.5 or more Profit Targets: 22-28, Can book some profits at first target and then trail SL further. Stop Loss: Below the current support, 19
NSE:SYNCOMFLong
by madhubansal
Aurobindo Pharma - Long Trade SetupHello, Auropharma near the resistance level of 1275 . You can enter long when price is crossed above 1275. *Confirmation of Trend Strength: A breakout above resistance indicates strong upward momentum and confirms the existing uptrend. This increases the likelihood of further price appreciation. * Reduced Risk: Trading with the trend minimizes the risk of opposing a large number of market participants who are also betting on the continuation of the uptrend. * Momentum: Breakouts often trigger a surge in buying pressure as traders rush to capitalize on the upward move, further propelling prices higher. * Clear Entry Signal: The breakout provides a well-defined entry point, allowing traders to enter the market with precision and confidence.
NSE:AUROPHARMALong
by piyushbafna000
Aurobindo Pharma - Long Trade SetupHello, Auropharma near the resistance level of 1275 . You can enter long when price is crossed above 1275. *Confirmation of Trend Strength: A breakout above resistance indicates strong upward momentum and confirms the existing uptrend. This increases the likelihood of further price appreciation. * Reduced Risk: Trading with the trend minimizes the risk of opposing a large number of market participants who are also betting on the continuation of the uptrend. * Momentum: Breakouts often trigger a surge in buying pressure as traders rush to capitalize on the upward move, further propelling prices higher. * Clear Entry Signal: The breakout provides a well-defined entry point, allowing traders to enter the market with precision and confidence.
NSE:AUROPHARMALong
by piyushbafna000
Pharma Sector Shines Amidst Market WeaknessOn December 19, 2024, the pharmaceutical sector in India experienced a notable uptrend, with the Nifty Pharma index rising over 1.8%, making it the only sector to gain in an otherwise weak market. The significant surge in delivery volume indicates a substantial influx of foreign capital into the sector. ◉ Several factors contributed to this positive movement: 1. Defensive Nature of the Sector: Amidst economic uncertainties, investors often turn to defensive sectors like pharma, which offer relatively lower risk compared to cyclical sectors. 2. Positive Market Sentiment: The overall sentiment for the pharma sector was buoyed by expectations of strong growth in the Indian pharmaceutical market, projected to reach $130 billion by 2030 and $450 billion by 2047. 3. Resilient to US Tariffs: India is a major supplier of generic drugs to the US, which could help shield this sector from tariffs due to its critical role in healthcare and the ongoing demand for affordable medications. ◉ Specific Stock Performances: 1. Ipca Laboratories NSE:IPCALAB : Up 5.4% ➖ The stock has formed a Bullish Pole & Flag pattern, and following a breakout, it is set to continue its upward movement. 2. Dr. Reddy's Laboratories NSE:DRREDDY : Up 4.3% ➖ The price has broken out of a falling trendline, signalling strong bullish momentum. ➖ This breakout, supported by a significant rise in trading volume, indicates growing investor interest. 3. Abbott India NSE:ABBOTINDIA : Up 3.4% ➖ The stock is currently in a consolidation phase within a parallel channel. ➖ After rebounding from the lower boundary, the price is now on an upward trend. ◉ Conclusion The Pharma sector's strong performance is driven by key players' impressive gains, contrasting with the broader market's decline. This divergence makes the sector an attractive investment opportunity. With a promising outlook and strong fundamentals, the Pharma sector is well-positioned for continued growth.
NSE:CNXPHARMALong
by GoodluckCapital
Short Term Trading idea in Dr. Lal Pathlabs, 17% upside possibleHello everyone, i hope you all will be doing good in your life and your trading as well. Today i have just brought a short term idea in Lab stocks. Stock name is Dr. Lal Pathlabs Ltd. and it is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. Stock has given near term consolidation breakout on daily and weekly time frame. Stock can travel towards all time high levels from here, I have already mention all the levels like stop loss and Targets. Stock is really good for long term investing as well. But for now i have just added kind of short term Idea. Please follow the levels. Market Cap ₹ 29,198 Cr. Current Price ₹ 3,494 High / Low ₹ 3,525 / 1,943 Stock P/E 76.5 Book Value ₹ 222 Dividend Yield 0.69 % ROCE 25.2 % ROE 20.4 % Face Value ₹ 10.0 Industry PE 53.6 Debt ₹ 247 Cr. EPS ₹ 45.7 Promoter holding 54.6 % Intrinsic Value ₹ 743 Pledged percentage 0.00 % EVEBITDA 40.4 Change in Prom Hold 0.00 % Profit Var 5Yrs 12.4 % Sales growth 5Years 13.1 % Return over 5years 20.9 % Debt to equity 0.13 Net profit ₹ 386 Cr. ROE 5Yr 21.3 % Profit growth 44.6 % Earnings yield 1.97 % PEG Ratio 6.15 Disclaimer:- Please always do your own analysis or consult with your financial advisor before taking any kind of trades. Dear traders, If you like my work then do not forget to hit like and follow me, and guy's let me know what do you think about this idea in comment box, i would be love to reply all of you guy's. Thankyou.
NSE:LALPATHLABLong
by TraderRahulPal
1
WOCKPHARMA: W pattern breakout may drive the price higher! The 1700-1800 range has acted as a formidable barrier for this stock, with the price faced rejection at these levels on two separate occasions. After experiencing a significant downturn, the price eventually found support around the 135 level, led the price to a period of consolidation. During this time, the stock developed a Double Bottom pattern. Following a substantial gap, it successfully broke out of the Double Bottom pattern with strong trading volume and is now positioned just above that breakout level. At present, the stock is trading at nearly half its all-time high, making it an appealing option right now.
NSE:WOCKPHARMALong
by GoodluckCapital
2
Thyrocare Technologies in Buying Zone with Strong Sales GrowthNSE:THYROCARE Thyrocare Technologies has shown a strong breakout after a long period of consolidation, supported by robust sales growth and consistent profitability. The stock is in a buying zone with strong volume, presenting a promising opportunity for investors. Fundamentals: Strong sales growth Good dividend player Consistent profitable growth Technical: Strong volume peak after consolidation, indicating potential buying interest Stock is in a buying zone May retest, so consider buying in small lots Good liquidity
NSE:THYROCARELong
by hrishikeshrahalkar
WANBURY LTD: 17-Year Resistance Shattered! Is This Pharma Stock WANBURY LTD: Breaking Resistance Like It's Going Out of Style! Technical Analysis: Breakout: Hold onto your hats, folks! Wanbury just smashed through a 17-year resistance level like a bull in a china shop... if the china shop had been reinforced for 17 years! Trend: The stock is in a strong uptrend, climbing faster than a squirrel on an espresso-coated tree. Volume: Huge volume activity observed. Traders are piling in like it's Black Friday at a discount pharmacy! Candle Pattern: That breakout candle is so bullish, it's practically wearing horns and pawing the ground. Support Levels: Previous resistance at 173.68 now likely to act as support. It's like the floor just became the ceiling, and Wanbury is redecorating the whole house! Fundamental Factors: Pharmaceutical sector seeing increased interest. Wanbury's producing more buzz than a beehive in a coffee shop. Potential new product launches or regulatory approvals could be fueling the rally. Risks: After such a strong move, a pullback is possible. Even rockets need to refuel sometimes! Keep an eye on broader market sentiment and sector-specific news. Trade Idea: Consider long positions with a stop loss below the breakout level. Target the psychological 200 level - it's time for Wanbury to join the 200 club! Remember, traders, timing is everything. You don't want to be fashionably late to this 17-year breakout party! Key Levels to Watch: Resistance turned support: 173.68 Next psychological resistance: 200.00 Stop loss consideration: Below 170.00 Disclaimer: This analysis is for educational purposes only. Always do your own research and manage your risk. Remember, the stock market is like a rollercoaster - thrilling, but it helps to have a strong stomach and know when to exit!
NSE:WANBURYLong
by TRADING-NASA
Suven Pharma Breaks Out Like a Fever Dream"Suven Pharma Breaks Out Like a Fever Dream! 💊📈 #PharmaStocksGoBoom" I. Current Price Action: Price: ₹787.35 Change: +58.10 (+7.97%) Volume: 3.673M (Higher than the number of pills in your grandma's medicine cabinet!) II. Key Observations: Breakout Bonanza: SUVENPHAR has busted through its long-term resistance faster than a hypochondriac racing to WebMD. Side Channel Escape: The stock just broke out of its side channel, showing more excitement than a kid in a candy store (or should we say, pharmacy?). Volume Surge: Trading volume is higher than the line at the doctor's office during flu season. This suggests strong conviction in the move. Support Levels: The previous resistance around ₹760 could now act as support. If it holds, it'll be stronger than the taste of cough syrup. III. Trading Idea: For the brave pill-poppers (I mean, traders), riding this breakout could be more thrilling than reading the side effects on a medication leaflet. But remember, chasing stocks can be as dangerous as self-diagnosing on the internet! Potential Targets: 🎯 Short-term: ₹820 (As ambitious as promising to exercise more) 🎯 Mid-term: ₹850 (Reaching for the stars, or at least the top shelf of the medicine cabinet) IV. Risks: If this breakout fails, the stock could drop faster than your New Year's resolution to eat healthier. Keep an eye on overall market health and be ready to take your profits before they expire like old medication. V. Final Thoughts: Suven Pharmaceuticals has finally broken out of its consolidation, potentially setting the stage for a rally that could cure your portfolio's ailments. Will it continue to climb, or suffer from nasty side effects? Only time will tell, but one thing's for sure – this stock is more exciting than reading the fine print on a prescription label! Disclaimer: This analysis is about as reliable as WebMD's symptom checker. Always do your own research and consult a financial advisor before making investment decisions. Happy trading, and may your profits be as plentiful as the pills in a pharmacy! 💊🚀
NSE:SUVENPHARLong
by TRADING-NASA